Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 10/20 | 0.47 |
| ▸ | THRB | P10828 | 5/20 | 0.47 |
| ▸ | CNR2 | P34972 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10090961 | 0.99 | GAA (0.49) | GAATP53THRBCNR2LMNA | |
| SCHEMBL1175353 | 0.89 | CNR2 (0.59) | GAATP53THRBCNR2LMNA | |
| SCHEMBL1175356 | 0.89 | CNR2 (0.59) | GAATP53THRBCNR2LMNA | |
| SCHEMBL10090970 | 0.89 | GRM2 (0.45) | CNR2 | |
| SCHEMBL10091012 | 0.88 | CNR2 (0.44) | GAATP53THRBCNR2LMNA | |
| SCHEMBL1174537 | 0.87 | CNR2 (0.51) | TP53THRBCNR2LMNA | |
| SCHEMBL1174532 | 0.87 | CNR2 (0.51) | TP53THRBCNR2LMNA | |
| SCHEMBL10091057 | 0.86 | POLB (0.47) | GAATP53THRBCNR2LMNA | |
| SCHEMBL10091075 | 0.86 | CNR2 (0.45) | CNR2 | |
| SCHEMBL10090957 | 0.86 | POLB (0.49) | GAATP53THRBCNR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835422-B2 | Substituted imidazoheterocycle derivatives | CARA THERAPEUTICS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835422-B2 | Substituted imidazoheterocycle derivatives | CARA THERAPEUTICS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120015930-A1 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CARA THERAPEUTICS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015930-A1 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CARA THERAPEUTICS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2010068520-A2 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CARA THERAPEUTICS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015930-A1 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CNR1, CNR2, HRH1 | GAA 4374/4885TP53 4265/4885THRB 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.